A | REALITY. The implementation of patientless trials will be driven by advancements in technology, and when technology is concerned, nothing really is fantasy. For example, we now take for granted telesurgery: a procedure performed by a doctor considerably distant from the patient, using medical robotics and multimedia image communication. I anticipate the adoption of patientless trials to be gradual, starting with the reduction or elimination of placebo arms and moving into studies assessing next-in-class molecules. Eventually, sophisticated and accurate algorithms will be developed that will allow for data to be fed into computer-generated clinical trial models, and robust output could be substituted for some clinical trial data.
TOMASZ SABLINSKI, MD, PH.D. is cofounder and CEO of Transparency Life Sciences.